Trius Announces Publication Of Tedizolid ESTABLISH 1 Trial In JAMA

Key findings include: A once-daily tablet of tedizolid, given over six days, is as effective as a Zyvox (linezolid) tablet given twice a day for 10 days. This is the first published Phase 3 study under new FDA draft guidelines for acute bacterial skin and skin structure infections (ABSSSI), which call for evaluating a response to antibiotics two-to-three days after starting treatment. Response was seen in two to three days, which was a strong predictor of outcomes at the end of therapy (day 11)...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Clinical Trials / Drug Trials Source Type: news